In addition to the types of liver diseases mentioned in this article, it has also been reported (Kain et al., 2020) that Nutlin-3 (a commonly used, highly selective, membrane-permeable MDM2 antagonist) can reduce the plasmodium liver stage infection by activating the p53-SLC7A11-GPX4 signaling pathway. This evidence concerns the gene SLC7A11 and liver disorder.